% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Hilvo:144050,
author = {M. Hilvo and P. J. Meikle and E. R. Pedersen and G. S. Tell
and I. Dhar and H. Brenner$^*$ and B. Schöttker$^*$ and M.
Lääperi and D. Kauhanen and K. M. Koistinen and A. Jylhä
and K. Huynh and N. A. Mellett and A. M. Tonkin and D. R.
Sullivan and J. Simes and P. Nestel and W. Koenig and D.
Rothenbacher and O. Nygård and R. Laaksonen},
title = {{D}evelopment and validation of a ceramide- and
phospholipid-based cardiovascular risk estimation score for
coronary artery disease patients.},
journal = {European heart journal},
volume = {41},
number = {3},
issn = {1522-9645},
address = {Oxford},
publisher = {Oxford University Press},
reportid = {DKFZ-2019-01601},
pages = {371-380},
year = {2020},
note = {2020 Jan 14;41(3):371-380},
abstract = {Distinct ceramide lipids have been shown to predict the
risk for cardiovascular disease (CVD) events, especially
cardiovascular death. As phospholipids have also been linked
with CVD risk, we investigated whether the combination of
ceramides with phosphatidylcholines (PCs) would be
synergistic in the prediction of CVD events in patients with
atherosclerotic coronary heart disease in three independent
cohort studies.Ceramides and PCs were analysed using liquid
chromatography-mass spectrometry (LC-MS) in three studies:
WECAC (The Western Norway Coronary Angiography Cohort)
(N = 3789), LIPID (Long-Term Intervention with
Pravastatin in Ischaemic Disease) trial (N = 5991), and
KAROLA (Langzeiterfolge der KARdiOLogischen
Anschlussheilbehandlung) (N = 1023). A simple risk
score, based on the ceramides and PCs showing the best
prognostic features, was developed in the WECAC study and
validated in the two other cohorts. This score was highly
significant in predicting CVD mortality [multiadjusted
hazard ratios (HRs; $95\%$ confidence interval) per standard
deviation were 1.44 (1.28-1.63) in WECAC, 1.47 (1.34-1.61)
in the LIPID trial, and 1.69 (1.31-2.17) in KAROLA]. In
addition, a combination of the risk score with
high-sensitivity troponin T increased the HRs to 1.63
(1.44-1.85) and 2.04 (1.57-2.64) in WECAC and KAROLA
cohorts, respectively. The C-statistics in WECAC for the
risk score combined with sex and age was 0.76 for CVD death.
The ceramide-phospholipid risk score showed comparable and
synergistic predictive performance with previously published
CVD risk models for secondary prevention.A simple ceramide-
and phospholipid-based risk score can efficiently predict
residual CVD event risk in patients with coronary artery
disease.},
cin = {C070},
ddc = {610},
cid = {I:(DE-He78)C070-20160331},
pnm = {323 - Metabolic Dysfunction as Risk Factor (POF3-323)},
pid = {G:(DE-HGF)POF3-323},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:31209498},
doi = {10.1093/eurheartj/ehz387},
url = {https://inrepo02.dkfz.de/record/144050},
}